{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:22:05Z","timestamp":1787239325178,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.autrev.2010.03.002","type":"journal-article","created":{"date-parts":[[2010,3,22]],"date-time":"2010-03-22T04:22:58Z","timestamp":1269231778000},"page":"547-552","source":"Crossref","is-referenced-by-count":43,"title":["Bisphosphonates in patients with autoimmune rheumatic diseases: Can they be used in women of childbearing age?"],"prefix":"10.1016","volume":"9","author":[{"given":"In\u00e8s","family":"Losada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Di Gianantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Zen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.autrev.2010.03.002_bib1","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.beem.2008.07.001","article-title":"Bisphosphonates: how do they work?","volume":"22","author":"Papapoulos","year":"2008","journal-title":"Best Pract Res Clin Endrocrinol Metab"},{"key":"10.1016\/j.autrev.2010.03.002_bib2","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/1529-0131(200107)44:7<1496::AID-ART271>3.0.CO;2-5","article-title":"Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Adhoc Committee on Glucocorticoid-induced Osteoporosis","volume":"44","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.03.002_bib3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/(SICI)1096-9926(199908)60:2<68::AID-TERA10>3.0.CO;2-H","article-title":"Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats","volume":"60","author":"Patlas","year":"1999","journal-title":"Teratology"},{"key":"10.1016\/j.autrev.2010.03.002_bib4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s12018-007-9000-4","article-title":"Bisphosphonates in corticosteroid-induced osteoporosis","volume":"5","author":"Sambrook","year":"2007","journal-title":"Clinic Rev Bone Miner Metab"},{"issue":"2","key":"10.1016\/j.autrev.2010.03.002_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.autrev.2008.07.036","article-title":"Exploring the complex relationships between infections and autoimmunity","volume":"8","author":"Doria","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2010.03.002_bib6","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.amjmed.2005.11.034","article-title":"Long-term prognosis and causes of death in systemic lupus erythematosus","volume":"119","author":"Doria","year":"2006","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.autrev.2010.03.002_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2008.07.014","article-title":"Infections, rheumatism and autoimmunity: the conflicting relationship between humans and their environment","volume":"8","author":"Doria","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2010.03.002_bib8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.autrev.2007.11.004","article-title":"Preventive strategies in systemic lupus erythematosus","volume":"7","author":"Doria","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2010.03.002_bib9","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1136\/ard.2007.072157","article-title":"EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases","volume":"66","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2010.03.002_bib10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0049-0172(00)80011-6","article-title":"Management of corticosteroid-induced osteoporosis","volume":"29","author":"Olszynski","year":"2000","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2010.03.002_bib11","first-page":"1280","article-title":"Determinants of bone mass in systemic lupus erythematosus: a cross sectional study on premenopausal women","volume":"26","author":"Sinigaglia","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2010.03.002_bib12","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/1529-0131(199905)42:5<882::AID-ANR6>3.0.CO;2-C","article-title":"Frequency of fractures in women with systemic lupus erythematosus","volume":"42","author":"Ramsey-Goldman","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2010.03.002_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1507\/endocrj.53.27","article-title":"The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis","volume":"53","author":"Kaji","year":"2006","journal-title":"Endocr J"},{"issue":"2","key":"10.1016\/j.autrev.2010.03.002_bib14","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/TCRM.S3940","article-title":"Management of glucocorticoid-induced osteoporosis: role of teriparatide","volume":"5","author":"Migliaccio","year":"2009","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"10.1016\/j.autrev.2010.03.002_bib15","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/art.10835","article-title":"Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use","volume":"48","author":"Tektonidou","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2010.03.002_bib16","first-page":"144","article-title":"Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy","volume":"28","author":"Maksmymowych","year":"2001","journal-title":"J Rheumatol"},{"issue":"346","key":"10.1016\/j.autrev.2010.03.002_bib17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.amjmed.2008.12.004","article-title":"Safety of bisphosphonates in the treatment of osteoporosis","volume":"122","author":"Recker","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2010.03.002_bib18","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00431-003-1298-4","article-title":"The role of bisphosphonates in diseases of childhood","volume":"162","author":"Srivastra","year":"2003","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.autrev.2010.03.002_bib19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.autrev.2010.03.002_bib20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanism of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Oteoporos Int"},{"key":"10.1016\/j.autrev.2010.03.002_bib21","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0090-9556(25)08972-X","article-title":"Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals","volume":"19","author":"Lin","year":"1991","journal-title":"Drug Metab Dipos"},{"key":"10.1016\/j.autrev.2010.03.002_bib22","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00198-009-0983-1","article-title":"Maternal and fetal outcome after long-term bisphophonate exposure before conception","volume":"21","author":"Hassen-Zrour","year":"2010","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.autrev.2010.03.002_bib23","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0041-008X(71)80008-X","article-title":"The effects of disodium etidronate on the reproductive functions and embryogenesis of albino rats and New Zealand rabbits","volume":"18","author":"Nolen","year":"1971","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"10.1016\/j.autrev.2010.03.002_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2131\/jts.20.SupplementI_1","article-title":"Intravenous reproductive and developmental toxicity studies of cimadronate (YM175), a novel bisphosphonate, in rats and rabbits","volume":"20","author":"Okazaki","year":"1995","journal-title":"J Toxicol Sci"},{"key":"10.1016\/j.autrev.2010.03.002_bib25","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.reprotox.2006.05.009","article-title":"The outcome of pregnancy following pre-pregnancy or early pregnancy alendronte treatment","volume":"22","author":"Ornoy","year":"2006","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.autrev.2010.03.002_bib26","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bone.2008.11.001","article-title":"Pregnancy outcome following in utero exposure to bisphosphonate","volume":"44","author":"Levy","year":"2009","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.autrev.2010.03.002_bib27","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/bdra.10016","article-title":"No effects of bisphosphonates on the human foetus","volume":"67","author":"Rutgers-Verhage","year":"2003","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"10","key":"10.1016\/j.autrev.2010.03.002_bib28","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1359\/JBMR.040711","article-title":"Maternal and foetal outcome after long-term pamidronate treatment before conception: a report of two cases","volume":"19","author":"Munns","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.autrev.2010.03.002_bib29","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1210\/jc.2005-2548","article-title":"Maternal and infant outcome after pamidronte treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception; a report of four cases","volume":"91","author":"Chan","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.autrev.2010.03.002_bib30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0936-6555(05)80667-3","article-title":"Malignant hypercalcemia in pregnancy and antenatal administration of intravenous pamidronate","volume":"8","author":"Illidge","year":"1996","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.autrev.2010.03.002_bib31","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/01.AOG.0000209183.39581.e9","article-title":"Malignant hypercalcemia in pregnancy: effects of pamidronate on uterine contractions","volume":"108","author":"Culbert","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"11","key":"10.1016\/j.autrev.2010.03.002_bib32","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/ard.49.11.955-a","article-title":"Antenatal administration of aminopropylidene diphosphonate","volume":"49","author":"Dunlop","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2010.03.002_bib33","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00198-003-1399-y","article-title":"Pharmacovigilance study of alendronate in England","volume":"14","author":"Biswas","year":"2003","journal-title":"Osteopros Int"},{"issue":"2","key":"10.1016\/j.autrev.2010.03.002_bib34","first-page":"344","article-title":"Maternal and fetal outcome of pamidronate treatment before conception: a case report","volume":"25","author":"Cabar","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2010.03.002_bib35","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.bone.2008.01.001","article-title":"Effects of alendronate and pamidronate on cultured rat metatarsal bones: failure to prevent dexamethasone-induced growth retardation","volume":"42","author":"Heino","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.autrev.2010.03.002_bib36","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s00223-001-2036-4","article-title":"Effects of long term administration of clodronate on growing rat bone","volume":"69","author":"Koivukangas","year":"2001","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"10.1016\/j.autrev.2010.03.002_bib37","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jpeds.2006.03.013","article-title":"Early bisphosphonate treatment in infants with severe osteogenesis imperfecta","volume":"149","author":"Antoniazzi","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.autrev.2010.03.002_bib38","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/1529-0131(200009)43:9<1960::AID-ANR6>3.0.CO;2-J","article-title":"Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children","volume":"9","author":"Bianchi","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2010.03.002_bib39","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00005792-199707000-00005","article-title":"Long-term effects of bisphosphonates on the growing skeleton: studies of young patients with severe osteoporosis","volume":"76","author":"Brumsen","year":"1997","journal-title":"Medicine"},{"issue":"10","key":"10.1016\/j.autrev.2010.03.002_bib40","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1359\/jbmr.2000.15.10.2052","article-title":"Intravenous pamidronate for treatment of reflex sympathetic dystrophy during breast feeding","volume":"15","author":"Siminoski","year":"2000","journal-title":"J Bone Miner Res"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997210000583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997210000583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:52:49Z","timestamp":1739965969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997210000583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S1568997210000583"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2010.03.002","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}